Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Corporation (GERN) CEO John Scarlett on Q1 2021 Results - Earnings Call Transcript
10:39pm, Monday, 10'th May 2021
Geron Corporation (GERN) CEO John Scarlett on Q1 2021 Results - Earnings Call Transcript
Geron: Q1 Earnings Insights
04:47pm, Monday, 10'th May 2021
Shares of Geron (NASDAQ:GERN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 12.50% over the past year to ($0.09), which missed the estim
SHAREHOLDER ALERT: Geron Corporation (GERN) Officers and Directors Under Investigation for False Statements and Insider Trading
09:30am, Monday, 19'th Apr 2021
SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) relating to pos
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
10:41am, Wednesday, 14'th Apr 2021
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
07:30am, Tuesday, 13'th Apr 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-c
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Thursday, 18'th Mar 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock a
Why Geron Corporation Stock Is Falling Today
12:06pm, Friday, 12'th Mar 2021
The company released its latest quarterly update, and investors were not impressed.
Geron Corp (GERN) CEO John Scarlett on Q4 2020 Results - Earnings Call Transcript
10:45pm, Thursday, 11'th Mar 2021
Geron Corp (GERN) CEO John Scarlett on Q4 2020 Results - Earnings Call Transcript
Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
04:10pm, Thursday, 11'th Mar 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematolog
Geron's Earnings Outlook
10:08am, Wednesday, 10'th Mar 2021
Geron (NASDAQ:GERN) announces its next round of earnings this Thursday, March 11. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:40pm, Thursday, 04'th Mar 2021
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
04:45pm, Monday, 01'st Mar 2021
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday,
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Thursday, 18'th Feb 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock a
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:45pm, Thursday, 21'st Jan 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock a
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
04:45pm, Thursday, 14'th Jan 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Offic
